<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: To examine CD44H and CD44v3 expression in <z:mpath ids='MPATH_458'>normal</z:mpath> gastric and small bowel mucosa, <z:mpath ids='MPATH_458'>normal</z:mpath> and Barrett oesophagus, and oesophageal epithelial <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> (<z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo> and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Ninety five specimens, comprised of 40 of <z:mpath ids='MPATH_458'>normal</z:mpath> oesophageal, gastric and small bowel mucosa, 22 of Barrett oesophagus (two with dysplastic changes), 20 of resected <z:mp ids='MP_0009308'>adenocarcinomas</z:mp>, and 13 of <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo>, were evaluated </plain></SENT>
<SENT sid="2" pm="."><plain>The samples were fixed in formalin and subsequently stained with anti-CD44H and anti-CD44v3 monoclonal antibodies using the avidin-<z:chebi fb="1" ids="15956">biotin</z:chebi> peroxidase technique </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: In contrast to <z:mpath ids='MPATH_458'>normal</z:mpath> oesophagus, which showed positivity for both CD44 <z:chebi fb="0" ids="53000">epitopes</z:chebi> (CD44H and CD44v3) in the basal third of the epithelium, antral and intestinal subtypes of Barrett oesophagus expressed CD44H only, the distribution being focal in non-dysplastic and diffuse in dysplastic Barrett mucosa </plain></SENT>
<SENT sid="4" pm="."><plain>Similarly, <z:mpath ids='MPATH_458'>normal</z:mpath> antral glands and small bowel epithelium were focally immunopositive for CD44H at the base of the crypts </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> <z:hpo ids='HP_0002860'>squamous cell carcinomas</z:hpo> were diffusely positive for both isoforms, whereas 75% (15/20) of the <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> expressed CD44H and 60% (12/20) expressed CD44v3 </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: CD44H is expressed in the proliferating areas of both <z:mpath ids='MPATH_458'>normal</z:mpath> squamous epithelium and Barrett mucosa </plain></SENT>
<SENT sid="7" pm="."><plain>CD44H expression seems to increase progressively in <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and infiltrating <z:mp ids='MP_0002038'>carcinoma</z:mp>, similar to the process described in the stomach </plain></SENT>
<SENT sid="8" pm="."><plain>CD44v3 expression, usually not observed in <z:mpath ids='MPATH_458'>normal</z:mpath> or neoplastic gastric mucosa, was present in <z:mpath ids='MPATH_458'>normal</z:mpath> squamous epithelium and oesophageal <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>CD44v3 immunoreactivity was also identified in 60% of <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>These findings suggest that CD44v3 may play a role in the development of oesophageal <z:mp ids='MP_0002038'>carcinoma</z:mp> of both squamous and glandular types </plain></SENT>
</text></document>